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Abstract
We sought to assess the performance of existing bleeding risk scores, such as HAS-BLED or 
OBRI, in patients with heart failure with reduced ejection fraction (HFrEF) in sinus rhythm (SR) 
treated with warfarin or aspirin. We calculated HAS-BLED and OBRI risk scores for 2,305 
patients with HFrEF in SR enrolled in the Warfarin versus Aspirin in Reduced Cardiac Ejection 
Fraction (WARCEF) trial. Proportional hazards models were used to test whether each score 
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predicted major bleeding, and comparison of different risk scores was performed using Harell’s c-
statistic and net-reclassification improvement (NRI) index. For the warfarin arm, both scores 
predicted bleeding risk, with OBRI having significantly higher c-statistic (0.72 vs 0.61; p=0.03) 
compared to HAS-BLED, though the NRI for comparing OBRI to HAS-BLED was not significant 
(0.32, 95% CI - 0.18-0.37). Performance of the OBRI and HAS-BLED risk scores were similar for 
the aspirin arm. For participants with OBRI score of 0 to 1, warfarin compared with aspirin 
reduced ischemic stroke (HR 0.51, 95% CI 0.26-0.98, p=0.042) without significantly increasing 
major bleeding (HR 1.24, 95% CI 0.66-2.30, p=0.51). For those with OBRI score of ≥2, there was 
a trend for reduced ischemic stroke with warfarin compared to aspirin (HR 0.56, 95% CI 
0.27-1.15, p=0.12), but major bleeding was increased (HR 4.04, 95% CI 1.99-8.22, p<0.001). In 
conclusion, existing bleeding risk scores can identify bleeding risk in HFrEF patients in SR, and 
could be tested for potentially identifying patients with a favorable risk / benefit profile for 
antithrombotic therapy with warfarin.
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Introduction
Patients with heart failure with reduced ejection fraction (HFrEF) may be at increased risk 
for ischemic strokes due to left ventricular thrombus formation and subsequent embolism.1,2 
Randomized clinical trials, such as the Warfarin and Antiplatelet Therapy in Chronic Heart 
Failure (WATCH) trial3 and the Warfarin versus Aspirin in Reduced Cardiac Ejection 
Fraction (WARCEF) trial,4 assessed whether warfarin therapy may benefit HFrEF patients 
who are in sinus rhythm (SR) and have no other indications for anticoagulation. Although 
warfarin therapy was found to reduce the risk of ischemic stroke in these trials, it also led to 
increased rates of major bleeding.3,4 A better characterization of bleeding risk in HFrEF 
patients who are in SR may therefore identify a subgroup of these patients who could benefit 
from anticoagulation. One potential approach is to consider existing bleeding risk scores, 
such as the HAS-BLED score and the Outpatient Bleeding Risk Index (OBRI), which has 
been used to predict risk of bleeding in patients receiving anticoagulation.5-9 The HAS-
BLED score, in particular, has demonstrated superior performance compared to other 
bleeding risk scores in patients with atrial fibrillation,6,10 while the OBRI has been noted to 
be simple to calculate and has been validated in outpatients receiving warfarin therapy for 
any indication.7,11 However, it is unknown whether these risk scores can also apply to 
HFrEF patients who are in SR treated with warfarin or aspirin. We therefore undertook the 
present analysis of the patients enrolled in the WARCEF trial, to determine whether HAS-
BLED and OBRI scores predicted bleeding risk in patients with HFrEF who are in SR, and 
to assess whether the effects of warfarin compared with aspirin varied depending on baseline 
risk of bleeding in this patient population.
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The protocol for the randomized, double blinded WARCEF trial (http://
www.ClinicalTrials.gov No. NCT00041938) has been described previously.4,12 Briefly, 
patients with left ventricular ejection fraction (LVEF) ≤35% and who were in SR were 
randomized to receive warfarin (target INR 2.75, with acceptable target range of 2.0 to 3.5) 
or aspirin (325mg daily). Additional eligibility criteria included being 18 years or older, 
having no contraindications to warfarin therapy, having a modified Rankin score of 4 or less 
(on a scale of 0 to 6, with higher scores indicating more severe disability), and treatment 
with a beta-blocker, an angiotensin-converting-enzyme (ACE) inhibitor or angiotensin-
receptor blocker (ARB), or hydralazine and nitrates. Patients were excluded if they had a 
clear indication for warfarin or aspirin, or if they had a condition that conferred a high risk 
of cardiac embolism, such as atrial fibrillation, a mechanical cardiac valve, endocarditis, or 
an intracardiac mobile or pedunculated thrombus. Patients were also excluded if they were 
unable to follow an outpatient study protocol, or if they were unable to provide informed 
consent. Patients in any NYHA functional class were eligible, although patients in NYHA 
class I could account for no more than 20% of the total sample. A total of 2,305 participants 
were recruited from 168 centers in 11 countries from October 2002 to January 2010. The 
investigation conforms with the principles outlined in the Declaration of Helsinki, and the 
Institutional Review Boards at the coordinating centers for all sites approved the study. All 
subjects provided informed consent. The maximum follow-up time was 6 years, and the 
minimum was 1 year.
Major bleeding was defined as intracerebral, epidural, subdural, subarachnoid, spinal 
intramedullary, or retinal hemorrhage; any other bleeding causing a decline in the 
hemoglobin level of more than 2 g per deciliter in 48 hours; or bleeding requiring 
transfusion of 2 or more units of whole blood, hospitalization, or surgical intervention. This 
definition corresponds closely to the definition for major bleeding recommended by the 
Internal Society on Thrombosis and Haemostasis.13 Ischemic stroke was defined as a 
clinically relevant new lesion detected on computed tomography or magnetic resonance 
imaging (MRI) or, in the absence of a new lesion, clinical findings that were consistent with 
the occurrence of clinical stroke and that lasted for longer than 24 hours. An independent 
end-point adjudication committee, whose members were unaware of the treatment 
assignments, adjudicated all bleeding and stroke events.
Demographic characteristics including age, sex, race/ethnicity, and body mass index (BMI) 
were determined at the initial study visit. Health behaviors were assessed by self-report at 
time of enrollment, including smoking status and alcohol consumption. Clinical 
characteristics that were collected include medical comorbidities (atrial fibrillation, 
hypertension, diabetes mellitus, history of myocardial infarction, and history of ischemic 
heart disease), history of stroke or transient ischemic attacks (TIAs), presence of liver 
impairment (defined as having an aspartate aminotransferase [AST] level of 114 IU/L, 
which represents three times the upper limit of normal), renal impairment (defined as having 
a creatinine clearance level of <30 ml/min, estimated through the Cockcroft-Gault equation), 
anemia (defined as having a hematocrit of <30%), left ventricular ejection fraction 
(measured by quantitative echocardiography or radionuclide or contrast ventriculography), 
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New York Heart Association (NYHA) functional class, and time-in-therapeutic range 
(calculated as the percentage of days when the INR is between 2.0 to 3.5). Additional details 
for these measures are as described previously.4
For each patient, the HAS-BLED risk score was calculated based on the approach described 
by Lip and colleagues,6 with modifications as described below. Because the HAS-BLED 
risk score was derived in patients on anticoagulation therapy, and because all patients in the 
WARCEF trial received either aspirin or warfarin but not both concurrently, the item for 
aspirin use in the HAS-BLED score was coded as 0 for all patients. Furthermore, for patients 
assigned to aspirin, the item for labile INR in the HAS-BLED score was coded as 0. For 
liver impairment, based on available data in WARCEF, we used a cut-off for AST level of 
>114 IU/L. The OBRI score was similarly calculated for each patient using the approach 
described by Beyth and colleagues.7 A brief summary of how HAS-BLED and OBRI risk 
scores were calculated is provided in Table 1.
Because bleeding risk is expected to differ for patients receiving warfarin and aspirin, we 
performed all analyses separately for the warfarin and aspirin arms of the WARCEF trial on 
an intent-to-treat (ITT) basis. For each arm, baseline demographic and clinical 
characteristics were compared between patients who had a major bleeding event during 
follow-up versus those who did not, using chi-squared tests for categorical variables and 
student’s t-tests for continuous variables. We further tabulated the proportion of participants 
with and without a major bleeding event by HAS-BLED and OBRI scores.
To assess whether HAS-BLED and OBRI scores were predictive of major bleeding, we 
constructed separate Cox proportional hazards models with the time to first major bleeding 
as the outcome and HAS-BLED or OBRI scores as ordinal predictor variables. We 
performed statistical testing for trend of increased risk of major bleeding associated with 
increased HAS-BLED or OBRI scores. We then calculated the c-statistics and the associated 
95% confidence intervals (CI) for each proportional hazards model using the R software 
package “survcomp”. We also compared ability of HAS-BLED and OBRI scores to classify 
bleeding risk for each arm by calculating the net reclassification improvement (NRI) index 
and its associated 95% CIs, using the R software package “nricens” as per the methods 
described by Pencina and colleagues.14 Because the NRI is sensitive to the selection of cut-
offs for defining risk categories,15 we used a two-category (i.e., high risk of bleeding versus 
low risk of bleeding) approach to calculate the NRI, based on the empirically observed rates 
of major bleeding across HAS-BLED and OBRI scores in the WARCEF trial.
We further constructed Cox proportional hazards models to assess the effect of warfarin 
versus aspirin on clinical outcomes, including death or ischemic stroke, ischemic stroke, and 
major bleeding, for subgroups of WARCEF participants defined by high versus low 
bleeding risk through HAS-BLED and OBRI scores. We also tested for interactions between 
treatment groups and bleeding risk for the above outcomes. P-values of <0.05 were 
considered statistically significant for all testing. All statistical analyses were conducted 
using SAS version 9.3 (SAS Institute, Cary, NC) or R version 3.0.1 (R Foundation for 
Statistical Computing, Vienna, Austria, 2013).
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The baseline characteristics of WARCEF participants by treatment group and bleeding risk 
are presented in Table 2. Of the 1,142 patients randomized to warfarin therapy, 66 (5.8%) 
experienced at least one major bleeding event. Those who experienced major bleeding were 
more likely to be 65 years or older, to be female, and to have renal impairment. For those 
randomized to aspirin, 31 (2.7%) of 1,163 patients had at least one major bleeding event, 
with those with major bleeding more likely to have lower BMI, to have had a prior stroke or 
TIA, to have renal impairment, and to have a previous history of alcohol use.
The distribution of HAS-BLED and OBRI scores for patients with and without major 
bleeding were calculated for each arm of the WARCEF trial (Table 3 and Figure 1). The 
proportion of patients who had any major bleeding on warfarin therapy was 5.3% for those 
with a HAS-BLED score of 0, increasing to 12.0% for those with a HAS-BLED score of 4 
or above (p=0.015 for trend). For those randomized to aspirin, the proportion of patients 
who had any major bleeding was 2.0% for those with a HAS-BLED score of 0, increasing to 
6.3% for those with a HAS-BLED score of 4 or above (p=0.04 for trend; Figure 1, top 
panel). Similarly, the proportion of patients who had any major bleeding on warfarin 
therapy was 4.0% for those with an OBRI score of 0, but was over 10% for those with an 
OBRI score of 2 or 3 (p=0.01 for trend; Figure 1, bottom panel). For patients randomized to 
aspirin, the proportion of those who had any major bleeding ranged from 2.6% for those 
with an OBRI score of 0 to 6.1% for those with an OBRI score of 3, but the increase was not 
statistically significant (p=0.38 for trend). Based on these results, for subsequent analyses, 
we defined a patient as having high risk of bleeding as having a score of 2 or above for 
OBRI and a score of 3 and above for HAS-BLED.
A comparison of the performance of HAS-BLED and OBRI scores for predicting time to the 
first major bleeding event is presented in Table 4. For the warfarin arm, the c-statistic for the 
OBRI score was 0.72 (95% CI, 0.62-0.81), which was significantly superior (p=0.003) to the 
c-statistic for the HAS-BLED score, although the NRI for comparing the OBRI to HAS-
BLED was not significant (0.32, 95% CI −0.18-0.37). For patients randomized to aspirin, 
the c-statistics for HAS-BLED and OBRI scores were similar, and the NRI for the OBRI 
score compared to the HAS-BLED score was not significant.
The treatment effect of warfarin versus aspirin on clinical outcomes and its interaction with 
major bleeding risk (categorized by OBRI and HAS-BLED scores) are presented in Figure 
2. For the outcome of major bleeding, there was a significant interaction between the effect 
of warfarin versus aspirin and bleeding risk according to the OBRI score (p=0.006). Patients 
classified as high bleeding risk by an OBRI score of ≥2 had increased risk of major bleeding 
with warfarin compared with aspirin (hazard ratio [HR] 4.04, 95% CI 1.99-8.22, p<0.001), 
while bleeding risk was similar for warfarin versus aspirin in those classified as low 
bleeding risk by an OBRI score of 0 to 1 (HR 1.24, 95% CI 0.66-2.30; p=0.51). There was 
no significant interaction between warfarin versus aspirin and bleeding risk by the HAS-
BLED score (p=0.89), though warfarin compared with aspirin significantly increased major 
bleeding in the subgroup with low bleeding risk identified a HAS-BLED score of 0 to 2 (HR 
2.04, 95% CI 1.19-3.48; p=0.009).
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For the outcome of ischemic stroke, there was no significant interaction between warfarin 
versus aspirin and bleeding risk defined by either bleeding risk scores (p=0.93 for OBRI and 
0.48 for HAS-BLED). The effect of warfarin versus aspirin was similar across subgroups of 
bleeding risk, with warfarin significantly reducing ischemic strokes in patients classified as 
low bleeding risk by either score (Figure 2). For the composite outcome of death or ischemic 
stroke, the effect of warfarin versus aspirin was similar and non-significant across all 
bleeding risk subgroups, and there was no significant interaction between treatment 
assignment and bleeding risk subgroups identified with either score.
Discussion
In this retrospective analysis of patients enrolled in the WARCEF trial, we found that 
predictors of major bleeding differed between patients receiving warfarin and aspirin, 
suggesting that bleeding risk is affected by both anti-thrombotic choice and patient 
characteristics. Importantly, we confirmed that the HAS-BLED and OBRI bleeding risk 
scores can be used to predict major bleeding in HFrEF patients who are in SR. For patients 
assigned to warfarin, the OBRI score demonstrated superior discrimination to HAS-BLED, 
though the NRI for comparing the OBRI score to HAS-BLED was not significant, which 
may have been due to the relatively low number of bleeding events. For patients assigned to 
aspirin, the HAS-BLED risk score, but not OBRI, was predictive of major bleeding. 
Furthermore, we found that the increase in major bleeding for warfarin compared with 
aspirin varied by subgroups identified by the OBRI score, and that for WARCEF 
participants with an OBRI score of 0 or 1, warfarin reduced the risk of ischemic stroke but 
did not increase the risk of major bleeding.
Given the continued interest in identifying subgroups of heart failure patients that may 
benefit from anticoagulation,16 our analysis to assess bleeding risk in HFrEF patients who 
are in SR is a timely one. Previously published bleeding risk scores, such as the HAS-BLED 
and OBRI, were derived and validated in cohorts of patients with indications for 
anticoagulation such as atrial fibrillation or venous thromboembolism.6,7 Although the 
WARCEF trial excluded such patients, the performance of the HAS-BLED and OBRI scores 
are comparable to these earlier reports. For example, in an analysis of the Stroke Prevention 
Using an ORal Thrombin Inhibitor in Atrial Fibrillation (SPORTIF) III and V trials, Lip and 
colleagues reported that the c-statistics of previously reported bleeding risk scores, including 
the HAS-BLED and OBRI, ranged from 0.49 to 0.65 in a cohort of patients receiving 
warfarin or ximelagatran.6 Similarly, in another report by Burgess and colleagues, c-
statistics for various published bleeding risk scores ranged from 0.61-0.74 for a real-world 
cohort of patients on warfarin therapy for diverse indications.17 The c-statistic of 0.72 for 
the OBRI risk score for WARCEF participants assigned to warfarin therapy is therefore near 
the upper range of what has been reported previously, and suggests that the OBRI score may 
be a useful prediction tool to characterize risk of major bleeding for this patient population.
We also assessed the effect of warfarin versus aspirin on clinical outcomes for subgroups of 
WARCEF patients stratified by predicted bleeding risk. We demonstrated that among 
patients having an OBRI risk score of 0 or 1, who accounted for more than half of all 
ischemic strokes observed during the WARCEF follow-up period, warfarin therapy reduced 
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the risk of ischemic stroke compared with aspirin but did not significantly increase the risk 
of major bleeding. These results are broadly consistent with our previous subgroup analysis 
showing that younger patients (age <60 years) enrolled in the WARCEF trial had reduced 
risk of death, ischemic stroke, or intracranial hemorrhage with warfarin therapy compared to 
aspirin.18 In our current analysis, WARCEF participants with an OBRI risk score of 0 or 1 
included most patients younger than 60 years, but also many patients who are older. Taken 
together, this subgroup consists of nearly two thirds of all patients enrolled in the WARCEF 
trial and accounts for more than half of all ischemic stroke events observed during the 
follow-up period. The findings from the present analysis therefore provide important 
insights for predicting the potential outcomes of antithrombotic therapies for a large number 
of patients with HFrEF who are in SR.
Our findings also raise the possibility of using bleeding risk scores to inform patient 
selection for subsequent trials of novel anticoagulants. Previous studies have often described 
a positive correlation between risk of stroke and risk of bleeding in patients who are 
candidates for oral anticoagulation therapy, as many risk factors, such as advanced age and 
hypertension, are shared by both of these adverse outcomes.19,20 This overlap is a major 
challenge for the use of bleeding risk scores as a part of a personalized approach for 
choosing anticoagulation strategy, as patients identified as having high risk of stroke also 
often have high risk of bleeding.21 Our results address this challenge by showing that 
predicted bleeding risk could play an important role in patient selection for consideration of 
antithrombotic therapy. Although warfarin compared with aspirin reduced ischemic strokes 
in WARCEF participants with both high and low predicted bleeding risk, the significant 
interaction between treatment assignment and OBRI risk categories for the outcome of 
major bleeding suggests that patients at low predicted bleeding risk may avoid increased 
bleeding with anticoagulation. Given the emergence of new non-vitamin K oral 
anticoagulants that have demonstrated favorable safety and efficacy profiles compared to 
warfarin,22 these findings may be useful for the design of future trials investigating the role 
of these agents for ischemic stroke prevention in HFrEF patients in SR.
There are a number of limitations to our study. Our retrospective analysis of the WARCEF 
trial had only a modest number of stroke and bleeding events, and our findings therefore are 
necessarily hypothesis generating and will require confirmation. Highlighting the challenges 
of applying existing risk scores to new populations and datasets, we made slight 
modifications to the HAS-BLED score to apply it to the WARCEF population. Our analysis 
of the performance of the HAS-BLED and OBRI bleeding risk scores will thus require 
further validation in independent cohorts of HFrEF patients who are in SR. However, while 
a new risk score derived from WARCEF data may better predict bleeding risk and estimate 
treatment effect sizes for this patient population, it is also likely that a well-performing, 
previously established risk score accepted by clinicians and practice guidelines will have 
broader impact.23 Finally, since the WARCEF trial only enrolled patients with HFrEF who 
are in SR, our findings may not be applicable to other subgroups of heart failure patients.
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Figure 1. Proportion of patients with major bleedings, by HAS-BLED and OBRI risk scores and 
by treatment arm
P-values for trend were calculated using Cox proportional hazards models.
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Figure 2. The effect of warfarin versus aspirin on clinical outcomes for subgroups of WARCEF 
participants stratified by OBRI and HAS-BLED risk scores
P-values represent results of tests of interaction between treatment assignment and bleeding 
risk subgroups identified by OBRI and HAS-BLED risk score.
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